Amarin Corp Plc (AMRN)

[zz1]

VBru - Kiwi may have a point.
While R-It included patients with TG 135-499, the tertile analysis published in JACC this year indicated that patients with TG <100 in the lower fertile and above 500 in the upper textile were also captured in R-It due to the intra-patient variability of TG levels. As you correctly pointed out that the number of subjects were smaller in these two extremes.
However, if the FDA is going to consider TG>135, then 500+ would be included in such an analysis. One can argue that if the upper tertile of TG is being included in consideration by the FDA, then the lowest tertile may similarly warrant inclusion for consideration.
It may all come down to the number of subjects in these two extremes.
Just as LDL-C is no longer a required threshold to initiate Statin therapy in Type 2 Diabetics, similarly TG may disappear as a required threshold in initiating V in at risk patients.